cp-945598 and Body-Weight

cp-945598 has been researched along with Body-Weight* in 1 studies

Other Studies

1 other study(ies) available for cp-945598 and Body-Weight

Article	Year
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists. Journal of medicinal chemistry, 2009, Jul-23, Volume: 52, Issue:14 Obesity is a major clinical problem in the western world, and many molecular targets have been explored in the search for effective therapeutic agents. One of these, antagonism of the cannabinoid 1 (CB1) receptor, rose to prominence following reports demonstrating the positive modulation of food intake by the CB1 antagonist, rimonabant (3) (SR141716A). In the present study, various diaryl-pyrazole derivatives containing cycloalkyl building blocks were synthesized and tested for CB1 receptor binding affinities. Thorough structure-activity relationship (SAR) studies to optimize the pyrazole substituents led to several novel CB1 antagonists with K(i) Topics: Animals; Anti-Obesity Agents; Body Weight; Cattle; Drug Design; Eating; Humans; Lipids; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship	2009

Article

Year

Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.

Journal of medicinal chemistry, 2009, Jul-23, Volume: 52, Issue:14

Obesity is a major clinical problem in the western world, and many molecular targets have been explored in the search for effective therapeutic agents. One of these, antagonism of the cannabinoid 1 (CB1) receptor, rose to prominence following reports demonstrating the positive modulation of food intake by the CB1 antagonist, rimonabant (3) (SR141716A). In the present study, various diaryl-pyrazole derivatives containing cycloalkyl building blocks were synthesized and tested for CB1 receptor binding affinities. Thorough structure-activity relationship (SAR) studies to optimize the pyrazole substituents led to several novel CB1 antagonists with K(i)

Topics: Animals; Anti-Obesity Agents; Body Weight; Cattle; Drug Design; Eating; Humans; Lipids; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship

2009